Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Non-active placebo control Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine

NCT03560245
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bryostatin, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Fresno, California • Los Alamitos, California • Santa Ana, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

CAP-Ketamine for Antidepressant Resistant PTSD

NCT02655692
View directory record Official record
Conditions
PTSD, Posttraumatic Stress Disorder
Interventions
Ketamine, Placebo/Saline
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
West Haven, Connecticut • Minneapolis, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Results available

Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD

NCT01709695
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine Hydrochloride XR, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
8 Years to 15 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 26, 2026, 1:10 PM EDT
Recruiting Phase 2 Interventional

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

NCT05269628
View directory record Official record
Conditions
Multiple Sclerosis, Sleep, Pain
Interventions
Cannabidiol (CBD), Tetrahydrocannabinol (THC), Placebo CBD, Placebo THC
Drug
Lead sponsor
Tiffany J. Braley, MD, MS
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Early Phase 1 Interventional Results available

MEG Study of Acute STX209 Effects in ASD

NCT02278328
View directory record Official record
Conditions
Autism Disorder
Interventions
STX209 (15mg), placebo, STX209 (30mg)
Drug
Lead sponsor
Timothy Roberts
Other
Eligibility
14 Years to 17 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

NCT02528188
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
299
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Synaquell™ in Contact Sport Athletes

NCT06104670
View directory record Official record
Conditions
Healthy
Interventions
Synaquell(TM), Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis

NCT01243983
View directory record Official record
Conditions
Noninfectious Uveitis
Interventions
LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Random Nicotine Delivery on Smoking Cessation

NCT03674970
View directory record Official record
Conditions
Smoking Cessation, Cigarette Smoking, Smoking (Tobacco) Addiction
Interventions
Nicotine Film
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD

NCT00896038
View directory record Official record
Conditions
Alcoholism, Alcohol Dependence, Posttraumatic Stress Disorder
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Bright Light Treatment On Elders In a Long Term Care Environment

NCT01042587
View directory record Official record
Conditions
Behavioral Responses to Bright Light Therapy in Elders
Interventions
exposure to bright light, low luminosity red light
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Elizabethtown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Sep 26, 2026, 1:10 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

NCT07154706
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Taletrectinib, Placebo
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

NCT03875729
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
teplizumab, Placebo
Biological
Lead sponsor
Provention Bio, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
34
States / cities
San Diego, California • San Francisco, California • Walnut Creek, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

NCT00468130
View directory record Official record
Conditions
Autism
Interventions
Aripiprazole, Placebos
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

NCT02518945
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 26, 2026, 1:10 PM EDT
Recruiting Phase 1 Interventional

Pharmacologic Augmentation of TMS for Depression With D-serine

NCT06876129
View directory record Official record
Conditions
Depression
Interventions
TMS, D-serine, Placebo
Device · Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 26, 2026, 1:10 PM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

NCT05948553
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Results available

Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)

NCT04811339
View directory record Official record
Conditions
Diarrhea, COVID-19
Interventions
Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable, Placebo oral tablet without BSS
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Not applicable Interventional Results available

Empower: tDCS for Major Depressive Disorder at Home

NCT05202119
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial direct current stimulation, Sham Transcranial direct current stimulation
Device
Lead sponsor
Flow Neuroscience AB
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis

NCT03998488
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Fecal Microbiota Transplantation, Psyllium Husk Powder
Drug · Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 26, 2026, 1:10 PM EDT
Recruiting Not applicable Interventional

Treatment of Borderline Personality Disorder With rTMS

NCT07197502
View directory record Official record
Conditions
Borderline Personality Disorder, Borderline Personality, BPD - Borderline Personality Disorder
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

NCT00959426
View directory record Official record
Conditions
Obesity, Overweight, Healthy
Interventions
PF-04620110, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 6, 2010 · Synced Sep 26, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187471
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 26, 2026, 1:10 PM EDT